The USFDA carried out the inspection at the plant from May 6 to May 15
Drug maker Lupin on May 15 said it has received three observations from the US health regulator for its Aurangabad-based manufacturing facility.
The US Food and Drug Administration (USFDA) carried out the inspection at the plant from May 6 to May 15, Lupin said in a statement.
“The inspection at the Aurangabad facility closed with three observations. The company is confident of addressing them satisfactorily,” it added.
Shares of Lupin on May 15 ended 3.22 percent lower at Rs 783.10 apiece on the BSE.